69,207 Shares in ImmunityBio, Inc. (NASDAQ:IBRX) Bought by Advantage Alpha Capital Partners LP

Advantage Alpha Capital Partners LP acquired a new position in ImmunityBio, Inc. (NASDAQ:IBRX) in the third quarter, HoldingsChannel reports. The institutional investor acquired 69,207 shares of the company’s stock, valued at approximately $257,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Victory Capital Management Inc. lifted its position in shares of ImmunityBio by 16.0% in the 2nd quarter. Victory Capital Management Inc. now owns 19,953 shares of the company’s stock worth $126,000 after buying an additional 2,746 shares during the last quarter. Wealth Effects LLC lifted its holdings in ImmunityBio by 3.4% in the third quarter. Wealth Effects LLC now owns 90,500 shares of the company’s stock worth $337,000 after acquiring an additional 3,000 shares during the last quarter. Exchange Traded Concepts LLC boosted its stake in ImmunityBio by 8.4% in the third quarter. Exchange Traded Concepts LLC now owns 47,984 shares of the company’s stock valued at $178,000 after acquiring an additional 3,722 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in shares of ImmunityBio by 3.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 123,879 shares of the company’s stock valued at $667,000 after purchasing an additional 4,533 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of ImmunityBio by 22.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company’s stock valued at $99,000 after purchasing an additional 4,545 shares during the last quarter. Institutional investors own 8.58% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on IBRX. Piper Sandler reduced their price objective on ImmunityBio from $6.00 to $4.75 and set a “neutral” rating for the company in a research report on Monday, August 19th. D. Boral Capital restated a “buy” rating and set a $30.00 price target on shares of ImmunityBio in a research report on Thursday, November 21st. Finally, EF Hutton Acquisition Co. I upgraded shares of ImmunityBio to a “strong-buy” rating in a research report on Wednesday, October 23rd.

ImmunityBio Stock Performance

IBRX opened at $5.12 on Wednesday. The stock’s 50 day moving average price is $4.30 and its 200 day moving average price is $5.12. ImmunityBio, Inc. has a 12 month low of $3.10 and a 12 month high of $10.53.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.